The single-nucleotide polymorphisms +936 C/T VEGF and 2710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 769-778

  Rodrigues, Patricia ^a   Furriol, Jessica ^a   Tormo, Eduardo ^a   Ballester, Sandra ^a   Lluch, Ana ^a,b   Eroles, Pilar ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Breast cancer risk; Case control association study; Polymorphisms; Vascular endothelial growth factor

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; VEGF GENE; VEGFR1 GENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBROBLAST GROWTH FACTORS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS; YOUNG ADULT;

EID: 84863721711     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1980-1     Document Type: Article

References (43)

1. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168-183
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
3. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
4. Pollan M, Ramis R, Aragones N, Perez-Gomez B, Gomez D, Lope V, Garcia-Perez J, Carrasco JM, Garcia-Mendizabal MJ, Lopez-Abente G (2007) Municipal distribution of breast cancer mortality among women in Spain. BMC Cancer 7:78
5. Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265-271
6. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232-242
7. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer- analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78-85
8. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
9. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653-660
10. Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymph angio-genesis. Exp Cell Res 312:549-560
11. Murakami M, Nguyen LT, Zhuang ZW, Moodie KL, Carmeliet P, Stan RV, Simons M (2008) The FGF system has a key role in regulating vascular integrity. J Clin Invest 118:3355-3366
12. Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen PY, ZhuangZW, Black BL, SimonsM(2011)FGF-dependentregulation of VEGF receptor2 expressioninmice.JClin Invest 121:2668-2678
13. Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64:2941-2955
14. Linderholm B, Tavelin B, Grankvist K, Henriksson R (1998) Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 16:3121-3128
15. 0 UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245-1249
16. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56:2013-2016
17. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947-11954
18. Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, Park JY, Lee MH, Lee HC, Chung HY, Yu W (2006) Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology 71:266-272
19. Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS, Huang CJ, Wang CL, Chang HW (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13:165-172
20. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468-471
21. Wang K, Liu L, Zhu ZM, Shao JH, Xin L (2011) Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16, 703 individuals. Cytokine 56:167-173
22. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 8:R22
23. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15:1148-1152
24. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G, Forsti A (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647-3653
25. 0 UTR polymorphism reduces BRCA1-associ-ated breast cancer risk in Polish women. Cancer Lett 262:71-76
26. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G (2006) A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci USA 103:1406-1411
27. Ciribilli Y, Andreotti V, Menendez D, Langen JS, Schoenfelder G, Resnick MA, Inga A (2010) The coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compound. PLoS One 5:e10236
28. Kendall RL, Thomas KA (1993) Inhibition of vascular endothe-lial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90:10705-10709
29. Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, Resnick MA (2007) A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endo-thelial growth factor receptor 1. Mol Cell Biol 27:2590-2600
30. Kato M, Okugawa G, Wakeno M, Takekita Y, Nonen S, Tetsuo S, Nishida K, Azuma J, Kinoshita T, Serretti A (2009) Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsycho-pharmacol 19:718-725
31. Schulz S, Kohler K, Schagdarsurengin U, Greiser P, Birkenmeier G, Muller-Werdan U, Werdan K, Glaser C (2005) The human FGF2 level is influenced by genetic predisposition. Int J Cardiol 101:265-271
32. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:1928-1929
33. Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 9:208-221
34. Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl 3):4-10
35. Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580:2879-2887
36. Delli Carpini J, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13:43-58
37. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA (2008) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 111:157-163
38. Hu YF, Luscher B, Admon A, Mermod N, Tjian R (1990) Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev 4:1741-1752
39. Mermod N, Williams TJ, Tjian R (1988) Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 332:557-561
40. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443-448
41. Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D, Kogevinas M, Dosemeci M, Figueroa J, Chatterjee N, Tardon A, Serra C, Carrato A, Garcia-Closas R, Murta-Na-scimento C, Rothman N, Chanock SJ (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3:e29
42. Menendez D, Inga A, Resnick MA (2006) The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol 26:2297-2308
43. Shibuya M (2001) Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 33:409-420